Evidence map›Paper›PMID 35416538›Full record

ReviewCurrent urology reports2022

Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.

Claudia Manini, Estíbaliz López-Fernández, Charles H Lawrie, Annick Laruelle, Javier C Angulo, José I López

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claudia ManiniDepartment of Pathology, San Giovanni Bosco Hospital, 10154, Turin, Italy.
Estíbaliz López-FernándezFISABIO Foundation, 46020, Valencia, Spain.
Charles H LawrieMolecular Oncology Group, Biodonostia Research Institute, 20014, San Sebastian, Gipuzkoa, Spain.
Annick LaruelleBasque Foundation for Science, IKERBASQUE, 48011, Bilbao, Bizkaia, Spain.
Javier C AnguloClinical Department, Faculty of Medical Sciences, European University of Madrid, 28005, Madrid, Spain.
José I LópezDepartment of Pathology, Cruces University Hospital, Plaza de Cruces S/N, 48903, Barakaldo, Bizkaia, Spain. jilpath@gmail.com.ORCID http://orcid.org/0000-0003-0842-5348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewIntratumor heterogeneity (ITH) is an inherent characteristic of most tumors and its detection remains a key task for pathologists. However, the clinical significance of the degree of development of this feature is still poorly understood. RECENT

findingsA series of 28 clear cell renal cell carcinomas (CCRCC) have been exhaustively analyzed with two different sampling protocols [multisite tumor sampling (MSTS) and total sampling] to evaluate to what point the level (low vs. high) of histological ITH detected in routine practice influences tumor behavior and patients' survival. All CCRCC (n = 14) pursuing an aggressive clinical course presented low levels of ITH. A significant worse survival was detected in CCRCC with low ITH (p < 0.001). The simple quantification of the level of ITH using extensive sampling protocol may be of help in predicting tumor evolution, since all CCRCC with aggressive behavior demonstrated low levels of histological ITH.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsFemaleHumansMalePrognosisClear cell renal cell carcinomaMultisite tumor samplingPrognosisSurvivalTumor heterogeneity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.